ABVX
Abivax SA American Depositary SharesKey Statistics
About Abivax SA American Depositary Shares
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies aimed at treating chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis among other indications. The company distinguishes itself by utilizing a unique approach that integrates antibody-mediated therapies with proprietary compounds, addressing critical unmet medical needs in the healthcare sector. With a robust pipeline and a team of skilled scientists committed to advancing therapeutic innovation, Abivax presents an attractive investment proposition for institutional investors seeking to leverage growth opportunities within the immunotherapy landscape.
Fundamentals
| Revenue (TTM) | $4.92M |
| Gross Profit (TTM) | $4.92M |
| EBITDA | $-254.00M |
| Operating Margin | -4184.00% |
| Return on Equity | -157.10% |
| Return on Assets | -44.70% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $6.30 |
| Price-to-Book | 16.26 |
| Price-to-Sales (TTM) | 1635.45 |
| EV/Revenue | 157.63 |
| EV/EBITDA | -12.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 35.20% |
| Shares Outstanding | $79.77M |
| Float | $58.23M |
| % Insiders | 0.00% |
| % Institutions | 70.56% |
Historical Volatility
Volatility is currently contracting